TY - JOUR T1 - Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Healthcare Workers in Chicago JF - medRxiv DO - 10.1101/2020.09.11.20192385 SP - 2020.09.11.20192385 AU - John T. Wilkins AU - Elizabeth L. Gray AU - Amisha Wallia AU - Lisa R. Hirschhorn AU - Teresa R. Zembower AU - Joyce Ho AU - Naomi Kalume AU - Ojoma Agbo AU - Alex Zhu AU - Laura J. Rasmussen-Torvik AU - Sadiya S. Khan AU - Mercedes Carnethon AU - Mark Huffman AU - Charlesnika T. Evans Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/13/2020.09.11.20192385.abstract N2 - Background Identifying factors associated with SARS-CoV-2 infection among healthcare workers (HCW)s may help health systems optimize SARS-CoV-2 infection control strategies. Methods: We conducted a cross-sectional analysis of baseline data from the Northwestern HCW SARS-CoV-2 Serology Cohort Study. The Abbott Architect Nucleocapsid IgG assay was used to determine seropositivity. Logistic regression models (unadjusted and adjusted for demographics and self-reported community exposure to COVID-19) were fit to quantify the associations between occupation group, healthcare delivery tasks, and community exposure and seropositive status.Results 6,510 HCWs, including 1,794 nurses, and 904 non-patient facing administrators participated. The majority were women (79.6%), 74.9% were white, 9.7% were Asian, 7.3% were Hispanic and 3.1% were Black. The crude prevalence rate of seropositivity was 4.8% (95% confidence interval (CI): 4.6%-5.2%). Out-of-hospital exposure to COVID-19 occurred in 9.3% of HCWs and was strongly associated with seropositivity (OR=4.7, 95% CI: 3.5-6.4). When compared to administrators, nursing was the only occupation group with a significantly higher adjusted-odds (OR: 1.9, 95% CI: 1.3-2.9) of seropositivity. Exposure to COVID-19 patients was reported by 37.8% of participants and was associated with higher positivity than those not exposed (OR= 2.2, 95% CI: 1.6-3.0). Being exposed to patients receiving high-flow oxygen therapy, and hemodialysis also remained significantly associated with a 45% and 57% higher odds for seropositive status, respectively.Conclusions Exposure to COVID-19 patients, and longer duration patient therapies were each associated with higher risk for seropositive status; however, the community burden of COVID-19 remains a significant source of exposure to SARS CoV-2 infection among HCWs in Chicago.Competing Interest StatementConsulting fees from NGM Biopharmaceuticals (JTW); Research funding support received from Novo Nordisk, Eli Lily, United Healthcare Group (AW); Consulting fees from BioK+ (CTE).Funding StatementFunding: We would like to thank the Northwestern University Clinical and Translational Sciences Institute for and the Northwestern Memorial Foundation for their financial support of this research effort.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Northwestern University IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not available for public use. ER -